Literature DB >> 25210413

Loxapine inhalation powder (adasuve): a new and innovative formulation of an antipsychotic treatment for agitation.

Jose Valdes, Travis Shipley, Jose A Rey.   

Abstract

Loxapine inhalation powder (Adasuve): an innovative formulation of an antipsychotic treatment for agitation.

Entities:  

Year:  2014        PMID： 25210413      PMCID： PMC4159064     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  8 in total

1.  Effects of diagnosis and context on dangerousness.

Authors:  R L Binder; D E McNiel
Journal:  Am J Psychiatry       Date:  1988-06       Impact factor: 18.112

2.  Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine.

Authors:  Michael D Lesem; Tram K Tran-Johnson; Robert A Riesenberg; David Feifel; Michael H Allen; Robert Fishman; Daniel A Spyker; John H Kehne; James V Cassella
Journal:  Br J Psychiatry       Date:  2011-01       Impact factor: 9.319

3.  Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.

Authors:  Michael H Allen; David Feifel; Michael D Lesem; Daniel L Zimbroff; Ruth Ross; Patrik Munzar; Daniel A Spyker; James V Cassella
Journal:  J Clin Psychiatry       Date:  2011-10       Impact factor: 4.384

4.  Is bipolar disorder specifically associated with aggression?

Authors:  Javier Ballester; Tina Goldstein; Benjamin Goldstein; Mihaela Obreja; David Axelson; Kelly Monk; Marybeth Hickey; Satish Iyengar; Tiffany Farchione; David J Kupfer; David Brent; Boris Birmaher
Journal:  Bipolar Disord       Date:  2012-05       Impact factor: 6.744

5.  The expert consensus guideline series. Treatment of behavioral emergencies 2005.

Authors:  Michael H Allen; Glenn W Currier; Daniel Carpenter; Ruth W Ross; John P Docherty
Journal:  J Psychiatr Pract       Date:  2005-11       Impact factor: 1.325

6.  Prevalence and precipitants of aggression in psychiatric inpatient units.

Authors:  K Barlow; B Grenyer; O Ilkiw-Lavalle
Journal:  Aust N Z J Psychiatry       Date:  2000-12       Impact factor: 5.744

7.  Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine.

Authors:  Joseph Kwentus; Robert A Riesenberg; Morteza Marandi; Raymond A Manning; Michael H Allen; Robert S Fishman; Daniel A Spyker; John H Kehne; James V Cassella
Journal:  Bipolar Disord       Date:  2012-02       Impact factor: 6.744

8.  Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.

Authors:  Kathleen R Merikangas; Hagop S Akiskal; Jules Angst; Paul E Greenberg; Robert M A Hirschfeld; Maria Petukhova; Ronald C Kessler
Journal:  Arch Gen Psychiatry       Date:  2007-05
  8 in total
  2 in total

1.  State of Acute Agitation at Psychiatric Emergencies in Europe: The STAGE Study.

Authors:  Luis San; Josef Marksteiner; Peter Zwanzger; María Aragüés Figuero; Francisco Toledo Romero; Grigorios Kyropoulos; Alberto Bessa Peixoto; Roxana Chirita; Anca Boldeanu
Journal:  Clin Pract Epidemiol Ment Health       Date:  2016-10-27

Review 2.  The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review.

Authors:  Domenico de Berardis; Michele Fornaro; Laura Orsolini; Felice Iasevoli; Carmine Tomasetti; Andrea de Bartolomeis; Nicola Serroni; Alessandro Valchera; Alessandro Carano; Federica Vellante; Stefano Marini; Monica Piersanti; Giampaolo Perna; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Int J Mol Sci       Date:  2017-02-08       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.